4.0 Article

Diagnosis and treatment of iron overload

Journal

REVUE DE MEDECINE INTERNE
Volume 44, Issue 12, Pages 656-661

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.revmed.2023.07.002

Keywords

Iron overload; Iron chelators; Hemochromatosis; Dysmetabolic iron overload syndrome

Ask authors/readers for more resources

The etiological investigation of hyperferritinemia involves clinical examination and biological tests. Dysmetabolic iron overload syndrome is the most common iron overload disease, and the effectiveness of bloodletting therapy is uncertain. Type 1 genetic hemochromatosis results in iron accumulation, but phenotypic expression varies. Elastography can be used to identify hepatic fibrosis in cases of elevated ferritin levels. Chelators are used for iron overload associated with anemia, with hepatic iron content needing to be controlled. Deferoxamine is the preferred treatment for severe iron overload or emergency conditions.
Etiological investigation of hyperferritinemia includes a full clinical examination, with the measurement of waist circumference, and simple biological tests including transferrin saturation. The classification between hyperferritinemia without iron overload (inflammation, excessive alcohol intake, cytolysis, Lferritin mutation) or with iron overload is then relatively easy. Dysmetabolic iron overload syndrome is the most common iron overload disease and is defined by an unexplained serum ferritin level elevation associated with various metabolic syndrome criteria and mild hepatic iron content increase assessed by magnetic resonance imaging. Bloodlettings are often poorly tolerated without clear benefit. Type 1 genetic hemochromatosis (homozygous C282Y mutation on the HFE gene) leads to iron accumulation through an increase of dietary iron absorption due to hypohepcidinemia. More than 95% of hemochromatosis are type 1 hemochromatosis but the phenotypic expression is highly variable. Elastography is recommended to identify advanced hepatic fibrosis when serum ferritin exceeds 1000 mu g/L. Life expectancy is normal when bloodlettings are started early. Ferroportin gene mutation is an autosomal dominant disease with generally moderate iron overload. Chelators are used in iron overload associated with anaemia (myelodysplastic syndromes or transfusion-dependent thalassemia). Chelation is initiated when hepatic iron content exceeds 120 mu mol/g. Deferasirox is often used as first-line therapy, but deferiprone may be of interest despite haematological toxicity (neutropenia). Deferoxamine (parenteral route) is the treatment of choice for severe iron overload or emergency conditions.(c) 2023 Societe Nationale Francaise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available